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Abst ract  We investigated the potential of cross-over to the 
serotonin receptor (5HT3) antagonist ondansetron after 
protection failure with tropisetron. Several cases of com- 
plete protection were observed. These limited data suggest 
that there is an indication for retreatment with a different 
5HT3 antagonist after an initial failure to another and also 
stress the need and relevance for comparative studies 
between 5HT3 antagonists. 
Introduction 
With the introduction of selective serotonin receptor (5HT3) 
antagonists it has become possible to control cisplatin- 
induced emesis properly in over 70% of patients. After 
failure with these compounds, treatment with more con- 
ventional antiemetics is not effective (de Mulder et al. 
1990; Italian Group for Antiemetic Research 1993). In 
view of the similarity in the mechanism of action and the 
seemingly comparable fficacy data, few people consider 
cross-over from one 5HT3 antagonist to another appropri- 
ate. Nevertheless the preclinical data do not support this 
pessimistic approach (Seynaeve t al. 1991). To obtain data 
for further clinical research, we performed a pilot study on 
the possible potential of cross-over from one 5HT3 antag- 
onist to another after initial protection failure. 
Patients and methods 
In the framework of concurrent phase II protocols, cisplatin was 
administered ata dose of 70-80 mg/m -2 week1 for 6 weeks. Patients 
who were treated with 70 mg/m 2concurrently received etoposide 50 mg 
daily. Antiemetic prophylaxis consisted of 5 mg tropisetron i. v. 15 rain 
prior to chemotherapy on day 1 and a once-daily oral dose of 5 mg on 
days 2-5. The antiemetic response was assessed separately by patient 
diary cards for days 1 and 2-5 (worst-day analysis). In patients who 
experienced at least five episodes of vomiting or more than 4 h of 
nausea per 24 h, this regime was considered to have failed, and they 
received ondansetron for the corresponding period of the subsequent 
cycle. The cisplatin dose was not modified. Patients who failed 
exclusively on days 2-5 still received tropisetron in subsequent 
courses only on day 1. The ondansetron regimen was a single dose 
of 8 mg intravenously 30 min before start of chemotherapy on day 1 
and 8 mg orally twice daily on days 2-5. 
Also, for the ondansetron treatment, he antiemetic efficacy was 
assessed for days 1-5 separately with patient diary cards, using the 
same response criteria s mentioned above. For the analysis of cross- 
over efficacy only complete control (no nausea or vomiting) was 
considered of clinical benefit. 
Results 
Of 49 patients treated with tropisetron, 14 crossed-over to 
ondansetron after protection failure. The patient character- 
istics are shown in Table 1. The male preponderance is 
mainly related to the tumor types selected for the phase II 
studies. Of these 14 patients, 12 were crossed-over for 
days 2 -5  and 2 for day 1, reflecting the decreased activity 
of 5HT, antagonist for delayed nausea and vomiting. The 
numbers of cisplatin courses given prior to cross-over due 
to protection failure were one course (7 patients), two 
courses (3 patients), three courses (1 patient), and five 
courses (3 patients). Both patients who received ondanse- 
tron for the acute period had a complete response at the 
subsequent cycle. Of the 12 patients who received ondan- 
setron during the delayed period, 3 experienced a complete 
response (cycle 2). 
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Discussion 
Previous cross-over studies (de Mulder et al. 1990; Marty et 
al. 1990) have shown that protection from cisplatin-induced 
nausea nd vomiting with 5HT3 antagonists i possible after 
Table 1 Patient characteristics (NSCLC, non-small-ceil lung cancer; 
ACUP, adeno carcinoma of unknown primary) 
Number of patients 14 
Male/female 12/2 
Age (years) 
Median 53 
Range 30-72 
Primary tumor site 
Head and neck 5 
Melanoma 3 
Mesothelioma 2 
Lung (NSCLC) 2 
ACUP 1 
Testicular cancer 1 
Chemotherapy 
Cisplatin 70 mg/m -2 week-1 + etoposide 50 mg p.o./day 9 
Cisplatin 80 mg/m -2 week-1 5 
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vomiting because 12 of 14 patients initially failed to 
respond to tropisetron during this phase. In the light of 
this, the 3 cases of complete control achieved with ondan- 
setron are even more interesting. The important question 
obviously is whether retreatment with the same 5HT3 
antagonist would also have resulted in complete protec- 
tion. Data on this topic are markedly lacking. Although in 
incidental cases retreatment with the same 5HT3 antagonist 
yielded a better result in a subsequent cycle, it would 
appear highly unlikely that this would transform the out- 
come from failure (defined as more than five vomiting 
episodes and/or more than 4 h of nausea) to complete 
protection. Therefore we feel that our data indicate that 
there is need for further studies on retreatment with 5HT3 
antagonists after initial failure. Such studies should inves- 
tigate, in a randomized trial, the protection rates following 
retreatment with the same antagonist as well as the protec- 
tion offered by cross-over to another 5HT3 antagonist. 
the previous failure of more conventional antiemetic 
treatment, for instance high-dose metoclopramide. The 
same studies have shown that the opposite is not the case. 
Metoclopramide is ineffective if 5HT3 antagonists are 
ineffective. Because of the similar mechanism of action, 
oncologists have refrained from recommending cross-over 
to another 5HT3 antogonist (Seynaeva et al. 1991). How- 
ever, the presently available 5HT3 antagonists are different 
in their structure their receptor affinity and many other 
aspects, and data on preclinical cross-resistance are lacking. 
To obtain data justifying further large-scale studies we 
performed the present pilot study. These data, although 
limited, show that complete control with ondansetron can 
be obtained in patients previously failing with tropisetron. 
In addition the data also reflect the relative inefficacy of 
5HT3 antagonists for controlling delayed nausea and 
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